Who exactly is Gilead Science, the drug maker Covid-19?

Jakarta, CNBC Indonesia – Gilead Science Inc., a biopharmaceutical company remdesivir drug maker, is reported to be working with international partners to expand production of the coronavirus drug (Covid-19).

The company also expects to produce 1 million remdesivir in December 2020. “It is planned to be able to produce several million by 2021,” Reuters was quoted by Gilead as quoted by CNBC Indonesia on Friday (4/1/2020).

In late May, Gilead expects to produce 140,000. Later, the medication will be administered through a hospital infusion. Previously, the United States confirmed that remdesivir was clinically effective in treating crown patients. Remdesivir is an antiviral for the treatment of patients with Ebola.
From clinical trials of the US National Institute of Allergy and Infectious Diseases (NIAID). In the USA, about 31% of patients receiving a certain dose of remdesivir can recover. In a trial of 1,063 patients, the patient recovered in 11 days.

This is more effective than other drugs like placebo. Patients need more time to recover, that is, 15 days with the medicine.

Photo: Gilead Sciences CEO Daniel O’Day, Gilead Sciences Chief Executive Officer (CEO) Daniel O’Day,

Executive Director (CEO) Gilead Sciences Daniel O’Day said his company already has more than 50,000 experimental drugs ready to be distributed once US authorities issue permits for emergency use.

O’Day also said that the company has established constant communication with the United States Food and Drug Administration (FDA), and this communication has increased in intensity in recent days when the results of large Trials are starting to come out.

Gilead Sciences is a biopharmaceutical company based in Foster City, California, United States (USA) that researches, develops and markets medicines. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including two drugs for hepatitis C, Harvoni and Sovaldi.

In reference to the official website, the company was first listed on the Nasdaq Exchange, USA. USA, in January 1992 under the GILD share code. Its share price rose 1.03% to $ 84 / share at the close of business on Thursday, US time. USA (04/30/2020) or Friday morning Indonesian time.

Currently, the company’s data records, Gilead Science is backed by more than 11,000 employees. Its head office is in 333 Lakeside Drive, Foster City, California, 94404. Foster City is a city located in San Mateo County, California. Gilead was originally founded in the state of Delaware.

What about the performance of the Nasdaq-listed company?

According to data from the 2018 financial statements, cited in the exclusive CNBC program, issued in January 2020, of the company’s sales, the largest sale of HIV drugs was US $ 14.6 billion or equivalent to Rp 226 billion (assuming an exchange rate of Rp 15,500 / US $), then hepatitis C drugs valued at $ 3.7 billion (Rp. 57 billion) and lymphoma drugs at $ 264 million (Rp. 4 billion).

Meanwhile, the drugs in the third phase of the test are HIV and AIDS, drugs for liver disease, crown, lung disease, lymphoma, colitis (inflammation of the large intestine), and arthritis (arthritis).

Net profit
Referring to the company’s financial statements, total revenue for the first quarter of 2020 amounted to $ 5.5 billion, or Rp 85 billion, up 5% compared to the same period in 2019.

Photo: Gilead Q1 2020 performance Gilead Q1 2020 Performance

Net profit for the first quarter of 2020 was US $ 1.6 billion or Rp25 trillion, equivalent to US $ 1.22 per share, 21% less than in the same period of 2019.

Non-GAAP net income (generally accepted accounting principles ) for the first quarter of 2020 was US $ 2.1 billion or US $ 1.68 per share, stagnant compared to the same period in 2019.

In the fourth quarter of 2019, total revenue was recorded at US $ 5.9 billion compared to US $ 5.8 billion for the same period in 2018. While the net profit in the fourth quarter of 2019 was US $ 2.7 1 billion, from previous $ 3 million Non-GAAP net income was $ 1.7 billion, down from $ 1.9 billion.

Photo: Gilead Performance 2019 Gilead Performance 2019

Throughout 2019, Gilead’s total revenue reached $ 22.4 billion or Rp 347 billion, compared to $ 22.1 billion for 2018.

Total net income in 2019 was $ 5.4 billion or Rp 84 billion, slightly below 2018 at $ 5.5 billion. Meanwhile, non-GAAP net profit in 2019 was $ 8.5 billion, from $ 8.7 billion previously.

“Gilead’s performance in the first quarter shows our continued progress and highlights the strength of our underlying business,” said Daniel O’Day in a press release, quoted by CNBC Indonesia.

“Our focus now is on our work with remdesivir and our continued commitment to the people who depend on our medications today,” he emphasized.

[Gambas:Video CNBC]

(bag / bag)